幽门螺杆菌感染降低癌症免疫疗法的疗效：系统评价和荟萃分析。
Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
机构信息
Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiangxi Clinical Research Center for Gastroenterology, Nanchang, China.
出版信息
Helicobacter. 2023 Dec;28(6):e13011. doi: 10.1111/hel.13011. Epub 2023 Sep 3.
BACKGROUND
Cancer immunotherapy has shown promising results in several tumors, but its efficacy is influenced by the immune state of the body. Helicobacter pylori (H. pylori) infection can modulate the immune function of the body through various pathways, ultimately affecting the effectiveness of cancer immunotherapy.
AIM
In this meta-analysis, we aimed to explore the association between H. pylori infection and the efficacy of cancer immunotherapy.
METHODS
We conducted a comprehensive search of PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials to identify relevant articles. We extracted and pooled the hazard ratio (HR) of the overall survival (OS) and progression-free survival (PFS) by Review Manager 5.4.
RESULTS
Our analysis included four studies with a total of 263 participants. Compared to the control group, patients receiving cancer immunotherapy with H. pylori infection had a shorter OS (HR = 2.68, 95% CI: 2.00-4.11, p < 0.00001) and PFS (HR = 2.25, 95% CI: 1.66-3.60, p < 0.00001).
CONCLUSION
Our meta-analysis suggested that H. pylori infection has a detrimental effect on cancer immunotherapy.
背景
癌症免疫疗法在多种肿瘤中显示出了有前景的效果，但它的疗效受到身体免疫状态的影响。幽门螺杆菌（H. pylori）感染可以通过多种途径调节身体的免疫功能，最终影响癌症免疫疗法的效果。
目的
在这项荟萃分析中，我们旨在探讨 H. pylori 感染与癌症免疫疗法疗效之间的关联。
方法
我们全面检索了 PubMed、Embase、Web of Science 和 Cochrane 中央对照试验注册库，以确定相关文章。我们使用 Review Manager 5.4 提取并汇总了总生存（OS）和无进展生存（PFS）的风险比（HR）。
结果
我们的分析纳入了四项研究，共 263 名参与者。与对照组相比，接受癌症免疫疗法且 H. pylori 感染的患者 OS（HR=2.68，95%CI：2.00-4.11，p<0.00001）和 PFS（HR=2.25，95%CI：1.66-3.60，p<0.00001）更短。
结论
我们的荟萃分析表明，H. pylori 感染对癌症免疫疗法有不利影响。
Zotero 插件